Valion Bio: completes initial feasibility evaluation of LarmorBio BioScan-NMR

What happened Valion Bio issued a press release on Oct 15, 2026 announcing completion of an initial feasibility evaluation of LarmorBio's BioScan-NMR platform. The press release is filed as Exhibit 99.1 to the Current Report on Form 8-K and is incorporated by reference.

Key details

• The event was reported in an 8-K under Item 8.01, other events, dated Oct 15, 2026.
• The filing includes Exhibit 99.1, a press release dated Oct 15, 2026.
• The Current Report contains forward-looking statements and related risk language.

Why it may matter This filing reports Item 8.01 (other events), which covers press releases or developments the company has chosen to disclose outside its periodic reports. The filing does not show why the insider traded or why the company acted.